» Authors » Kanchana Than-In-At

Kanchana Than-In-At

Explore the profile of Kanchana Than-In-At including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 3
Citations 23
Followers 0
Related Specialty
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Cressey T, Salvadori N, Rabie H, du Toit S, Than-In-At K, Groenewald M, et al.
J Acquir Immune Defic Syndr . 2025 Feb; PMID: 39972540
Background: Dolutegravir dispersible tablets (DTG-DT) are approved for infants ≥4 weeks and ≥3 kg but their suitability for neonates remains unknown. Methods: PETITE-DTG is a Phase I/II, open-label, single center,...
2.
Bekker A, Salvadori N, Rabie H, du Toit S, Than-In-At K, Groenewald M, et al.
Lancet HIV . 2024 Jan; 11(2):e86-e95. PMID: 38296364
Background: Existing solid antiretroviral fixed-dose combination formulations are preferred over liquid formulations in children, but their suitability for neonates is unknown. We evaluated the pharmacokinetics and safety of paediatric abacavir-lamivudine...
3.
Bekker A, Rabie H, Salvadori N, du Toit S, Than-In-At K, Groenewald M, et al.
J Acquir Immune Defic Syndr . 2021 Dec; 89(3):324-331. PMID: 34855626
Background: Antiretroviral options for neonates (younger than 28 days) should be expanded. We evaluated the pharmacokinetics, safety, and acceptability of the "4-in-1" fixed-dose pediatric granule formulation of abacavir/lamivudine/lopinavir/ritonavir (30/15/40/10 mg)...
4.
Cressey T, Siriprakaisil O, Klinbuayaem V, Quame-Amaglo J, Kubiak R, Sukrakanchana P, et al.
BMC Infect Dis . 2017 Jul; 17(1):496. PMID: 28705153
Background: Tenofovir disoproxil fumarate (TDF) is key component of pre-exposure prophylaxis (PrEP) and antiretroviral therapy (ART) for HIV, but existing tools to monitor drug adherence are often inaccurate. Detection of...